Nasal composition and method for prevention and treatment of colds and influenza a virus

 

(57) Abstract:

Nasal composition includes pyroglutamic acid in concentrations of from 0.01 to 20% by weight of the composition, and other organic acid in an amount of from 0.01 to 10% by weight of the composition. Organic acid has the value of the dissociation constants (pKa) of from 3.0 to 5.0. The combination of these pyroglutamyl and organic acids on the surface tissue of the nasal cavity pH value of from 3.5 to 5.5. The composition is effective to prevent the onset of symptoms of colds and influenza viral origin or their significant mitigation, if the subject already suffering from such symptoms. 2 S. and 4 C.p. f-crystals.

The present invention relates to compositions and related methods of prevention and treatment of colds and flu-like symptoms caused by viral infections of the respiratory tract. These compounds and their method of application are effective to prevent the onset of symptoms of colds and flu, or their significant mitigation, if the subject already suffering from such symptoms.

It is known that many different viruses and virus strains cause symptoms associated with respiratory VIR is on the antigenic properties of the viruses, related to five virus families. These families include rhinovirus, myxovirus, paramyxovirus, respiratory syncytial virus, adenovirus and coronavirus. The most important group is the rhinovirus, J. M. Gwaltney, Common Cold, pp. 489-493, Mandell G. L., Douglas, R. G. Jr., Bennett, J. E., Principles and Practice of Infectious Diseases, 3rded., Churchill Livingstone, New York, 1990. The exact definition of specific causes is complex and is not practiced, because there are a number of predisposing factors that have contributed to the manifestation of symptoms is not fully understood. Such symptoms include, but are not limited to, physical fatigue, psychological stress, and overall physical health.

Not taking into account the virus and associated factors leading to the occurrence of symptoms of colds and flu, proposed a number of methods to relieve symptoms of the common cold. Products cough/colds, which are sold at the present time, typically contain one or more of the following active ingredients: anti-laid nose, such as pseudoephedrine, oximation, antigistaminny tools, such as doxylamine, antitussives, such dextromethorphan, expectorants, so the UDA experts in this field have proposed several alternative types of pharmacotherapy and subsequently tested for colds to test their effectiveness. Examples of such therapies include the use of interferon-2, Douglas et al. Prophylactic Efficacy of Intranasal Alpha2-Interferon Against Rhinovirus Infection in the Family Setting, The New England Journal of Medicine, 314, pp. 65-70, 1986; antagonist of bradykinin, Higgins et al. A Study of the Efficacy of the Bradykinin Antagonist, NPC567, in Rhinovirus Infection in Human Volonteers, Antiviral Research vol. 14, pp. 339-344, 1990; glucocorticoid, Farr et al., A Randomized Controlled Trial of Glucocorticoid Prophylaxis Against Rhinovirus Infection, Journal of Infectious Disease, vol.162, pp. 1173-1177, 1990; nedocromil, Barrow et al. The Effect of Intranasal Nedocromil Sodium on Viral Upper Respiratory Tract Infections in Human Volunteers, Clinical and experimental llergy, vol.20, pp. 45-51, 1990; combination of interferon-2, ipratropium and naproxen, Gwaltney. Combined Antiviral and Antimediator Treatment of Rhinovirus Colds, The Journal of Infectious Diseases, vol. 166, pp. 776-782, 1992; zinc salts, Potter et al., DIAS Rounds, Zinc Lozenges for Treatment of Common Colds, The Annals of Pharmacotherapy, vol.27, pp. 589-582, 1993.

It was also issued a number of patents relating to compositions for the prevention and treatment of the common cold and the ways of their treatment. Examples of such patents are U.S. patents 5240694, 5442097 and 5492689; all issued Gwaltney related to treatment with combinations of anti-virus and anti-inflammatory compounds; U.S. patent Re 33465 and 5409905; both issued Eby related to treatment with the use of zinc salts; U.S. patent 5626831, issued to Van Moerkerken, classifying the 9934 and 4552899, both issued Sunshine relating to the treatment of cough and colds using the compositions, including non-steroidal anti-inflammatory drugs, such as NSPs, materials with antihistamine action, such as chlorpheniramine.

Flu treatment includes vaccination and the use of specific antiviral drugs. The latter are disclosed in review A. Elliott and J. Ellis, 2000, Pharmaceutical Journal, 265, 446-451. Amantidine and rimantidine has been used to treat influenza infection. Target for their actions is a protein Ml of influenza virus, and they prevent the release of the genetic material of the virus in infected cells, thus preventing viral replication. It was reported some side effects, including neurological and gastrointestinal disorders, Belshe, R. B., Smith, M. H., Hall, S. C., Betts, R. J. Hay, Genetic Basis of Resistance to Rimantidine Merging During Treatment of Influenza Virus Infection, Journ. of Virology, 1988, 62, 1508-12; Hay, A. J., The Action of Adamantamines Against Influenza A Viruse; Inhibition of the M2 Ion Channel Protein. Semin. Virol., 1992, 3, 21-30.

Another approach to the treatment of flu treated molecule inhibition of the enzyme neuraminidase of the virus, important for the replication and infectivity of the virus. One of the drugs for such treatment is zanamivir, the development of the al. JAMA, 1999, 282, 31-5. Side effects reported, represented sinusitis, diarrhea, vomiting and harmful effect on the lungs. The second drug, inhibiting the neuraminidase is oseltamivir, licensed under the trade name Tamiflu ® ” (Tamiflu), Treanor J. J., F. G. Hayden, Vrooman P. S., Bararush R, Bettis R, Riff D. Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza: A randomized controlled Study. JAMA, 2000, 283, 1016-24.

In U.S. patent 4689223, issued August 25, 1987, transferred to T&R Chemicals, described the composition of the nasal sprays from the common cold for the treatment or prevention of symptoms, including sulfites or bisulfite with low, but not described specific pH. EP 046409, published February 24, 1982, issued Walliczek, describes how to obtain a solution of copper complexes for therapeutic treatment of humans or animals; included here as a reference. The method describes the obtaining of copper complexes with ascorbic acid or non-toxic ascorbate, having a pH of from 4 to 6. The complex can be used to obtain solutions for the local treatment of fungal, inflammatory or viral diseases. U.S. patent 6080783, issued June 27, 2000, submitted Gum Tech International, Inc. included here in cachedpage metal to the nasal membrane. The composition of the supports of the zinc ion in direct contact with the membrane of the nasal cavity and rapidly deliver zinc to the nasal membrane and into the bloodstream in these membranes for the treatment of colds.

Well-known characteristic of rhinoviruses is that they lose their infectivity in acidic conditions. It is known that even a pH value of 5.0, reduce the infectivity of rhinovirus, J. H. Hughes, Acid Lability of Rhinovirus Type 14: Effect of pH, Time and Temperature, Proc. Soc. Exp. Biol. Med., 1993, 144, 555-60. EP 310317, published April 5, 1989, issued by Bordt et al., transferred Beecham, describes a method for the inactivation of viruses and bacteria by means of pharmaceutical compositions, including vaccines, obtained by inactivation of the viruses or bacteria ascorbic acid or its salts in the presence of oxygen and heavy metal ions. U.S. patent 4767788, Diana, issued August 30, 1988, transferred to Sterling Drug, Inc., describes how the destruction of viruses, including rhinoviruses mucosa of the nasal cavity, glutaric acid.

Despite the large number of songs and preventive treatments known in this field, there remains a need for an appropriate and effective way to prevent and treat symptoms of colds and flu.

Definition

The following definitions, which should be attributed to the terminology used to describe the present invention.

Under “composition of the respiratory tract” refers to compositions in the form that can be delivered airbag is aspecialy, the spray pressure, spray guns, air inhalation, and other known or those that need to develop, package, and equipment.

Under “colds and flu-like symptoms” refers to the symptoms that are usually associated with viral infections of the respiratory tract. These symptoms include as non-limiting examples of nasal congestion, heaviness in the chest (chest congestion, sneezing, runny nose, fatigue or malaise, cough, fever, chills, body aches, sore throat, headache and other well-known colds and flu-like symptoms.

Under “respiratory viruses” refers to those viruses which are causal agents of colds and flu-like of sympotoms. These viruses include rhinovirus, myxovirus (influenza virus), paramyxovirus (parainfluenza virus), respiratory syncytial virus, adenovirus and coronavirus.

By “pharmaceutically acceptable carrier” refers to any solid, liquid or gas, combined with the compound in the compositions of the present invention for delivery of the compounds in the respiratory tract of the user. These carriers usually are considered bezopanikom and organic acid, possessing a pKa value of about 3.0 to 5.0, with the combination of these pyroglutamyl and organic acids provides the surface pH of the tissue of the nasal cavity approximately from 3.5 to 5.5. After application in the nasal tissues of the composition to create viruses adverse environment. This environment keeps the subject from infection by viruses responsible for the symptoms, mainly acknowledged above. The present invention also relates to the treatment of already infected subjects in order to mitigate the above mentioned symptoms of colds and flu. Part of the invention are also ways to reduce or eliminate the possibility of Contracting these viruses persons at high risk in the environment, including public buildings such as schools and work offices.

Pyroglutamyl acid

Nasal compositions of the present invention comprise a safe and effective amount pyroglutamic acid or PCA. When you use here under pyroglutamic acid collectively refers to its stereoisomers and tautomers. Pyroglutamyl acid, also known as pyrrolidinecarbonyl acid, has two stereoisomeric also known under the following names: D-Proline, 5-oxo-(+)-2-pyrrolidone-5-carboxylic acid, (+)-Pyroglutamate acid, (R)-2-pyrrolidone-5-carboxylic acid, 5-oxo-D-Proline, D-2-pyrrolidone-5-carboxylic acid, D-pyroglutamyl acid, D-pyrrolidinecarbonyl acid, and D-pyrrolidinecarbonyl acid.

L-stereoisomer pyroglutamic acid is also known under the following names: L-Proline, 5-oxo-(-)-2-pyrrolidone-5-carboxylic acid, (-)-Pyroglutamate acid, (53)-2-oxopyrrolidin-5-carboxylic acid, (S)-(-)-2-pyrrolidone-5-carboxylic acid, (S)-2-pyrrolidone-5-carboxylic acid, (S)-5-oxo-2-pyrrolidinecarbonyl acid, (S)-pyroglutamyl acid, 2-L-pyrrolidone-5-carboxylic acid, 2-pyrrolidinone-5-carboxylic acid, 5-carboxy-2-pyrrolidinone, 5-oxo-L-Proline, 5-oxoproline, 5-pyrrolidine-2-carboxylic acid, glutinosa (Glutimic) acid, glutinosa (Glutiminic) acid, L-2-pyrrolidone-5-carboxylic acid, L-5-carboxy-2-pyrrolidine, L-5-oxo-2-pyrrolidinecarbonyl acid, L-5-oxoproline, L-glutamic acid, gamma-lactam, L-glutinosa (Glutimic) acid, L-glutamina (Glutiminic) acid, L-pyroglutamyl acid, L-pyrrolidinecarbonyl acid, L-PIR oligocarbonate acid, oxoproline, PCA, pedolola (Pidolie) acid, pyroglutamyl acid, peforma pyroglutamic acid (mixture of D - and L-stereoisomers) is known under the following names: DL-Proline, 5-oxo-(.+-.)-2-pyrrolidone-5-carboxylic acid, (.+-.)-pyroglutamyl acid, 5-oxo-DL-Proline, DL-2-pyrrolidinone-5-carboxylic acid, DL-2-pyrrolidone-5-carboxylic acid, DL-Pyroglutamate, DL-Pyroglutamate acid, DL-pyrrolidone carboxylic acid and oxoproline. DL-form is also commercially available from Ajinomoto under the trade names Ajidew A 100 and Ajidew N-50 (Na-PCA).

Some of these stereoisomers are available commercially in UCIP, France, through Barnet Products Corp., New Jersey. Such compounds are sold under trade names such as Cuivridon (Cu-PCA), and L-FER Pidolate (Fe-PCA), and Pidolidone.

The compositions of the present invention include from about 0.01 to 20% pyroglutamic acid by weight of the composition, alternatively from about 0.1 to 10%, from about 0.25 to 8% and especially from about 1 to 5%.

Organic acids

In addition to PCA the present invention uses the organic acid to create compositions that are unfavorable for the above viruses. These organic acids are characterized by the dissociation constant (pKa) of from about 3.0 to 5. In combination with PCA, the composition has a high buffer capacity, providing surface pH of the cloth treated in the nasal on the 10,00%, alternative from about 0.05 to 5%, and especially from about 0.1 to 2.50% of the composition.

Organic acids which can be used according to the present invention, selected from the group consisting of ascorbic acid, mono-, di-, and tricarboxylic acids and mixtures thereof. Specific mono-, di - or tricarboxylic acid selected from the group consisting of salicylic, fumaric, benzoic, glutaric, lactic, citric, malonic, acetic, glycolic, malic, adipic, succinic, aspartic, phthalic, tartaric, glutamic, gluconic acid and mixtures thereof. The use of such acids is particularly unexpected for the person skilled in the art, in the sense that they create this unfavorable environment for viruses without significant irritation of the nasal tissues in contact with the compositions.

Funds are used to bring the pH of the composition of the present invention to values less than 4.5. Therefore, when the composition is applied to nazalnam tissues, the pH value of the composition to the nasal tissues remains approximately from 3.5 to 5.5, but it is not so low as to cause irritation to the nasal tissues. Such means of bringing the pH include those that are usually associated with the use of local nasal composicin, sodium citrate, and combinations thereof. They can be added directly to the composition or formed by the interaction within the composition during the process of bringing the pH. Means of bringing the pH is mainly present in the amount of approximately from 0.01 to 5.0% by weight of the composition.

Depending on the required shape and the delivery device to be used, the compositions of the present invention can include pharmaceutically acceptable carriers, including co-solvents, such as ethanol, propylene glycol, glycerin, not miscible with water, the solvent; liquid aerosol propellants, and mixtures thereof. Preferably, the data carriers are isotonic with blood plasma of man. It may also include preservatives to prevent microbial contamination of the metering devices or compositions introduced into the nose. Such preservatives include those that are typically associated with local naselenie compositions, including benzalconi-chloride, chlorhexidine gluconate, phenethyl alcohol, Phenoxyethanol, benzyl alcohol, sorbic acid, benzoic acid, thimerosal, acetate finalstate and combinations thereof.

The carrier may also contain surfactants, and, thickeners, mucoadhesive polymers and mixtures thereof may be included to slow down the normal physiological leaching solution from the nasal cavity into the oropharynx. When the compositions of the present invention are in the form of a liquid, the combination of ingredients is such that the viscosity of the final composition is less than 1000 centipoise when the pH of the composition is about 3.5.

Volatile oils, fragrances and flavorings may also be incorporated to provide required when using the smell and taste of the composition. Can also include homeopathic ingredients. Detailed, but not necessarily a complete list of such means is in The Homoeopathic Pharmacopoeia of the United States, 1999 ed., published by The Pharmacopoeia Convention of the American of Homeopathy, © 1982, Vol. 1-4.

Suitable mucoadhesive polymers used in the present invention, are sensitive to pH. Under the sensitivity to pH realize that after contact with body fluids or tissues of the mucous composition becomes sticky or stretchy enough for adhesion to the tissues and the absence of rapid leaching from the surface. This is due to the increase in pH during contact of the acidic product with less acidic mucous tissues and tissue fluids. This vest is more time compared to conventional liquid product. For example, in the case where the composition is a liquid applied using spray, spraying into the nasal cavity, the composition rapidly forms a gel-like film, which prevents leakage when sneezing, blowing the nose of the subject or mucociliary clearance.

Mucoadhesive polymers selected from the group consisting of carboxypolymethylene; carboxyvinyl polymers; homopolymers of acrylic acid crosslinked allyl simple ether of pentaerythritol; homopolymers of acrylic acid crosslinked allyl simple sucrose esters, homopolymers of acrylic acid crosslinked diphenylglycine, and mixtures thereof. The homopolymers of acrylic acid crosslinked allyl simple ether of pentaerythritol or an allyl simple sucrose esters, available from B. F. Goodrich Company under the trade name “carbopol” (Carbopol). Specific carbopol include Carbopol 934, 940, 941, 956, 980, and mixtures thereof. In the implementation of the present invention used concrete Carbopol 980. Polymers of this type have as Vice weakly acidic carboxyl group. Such polymers in water usually have a pH of about 3 and is mainly used by neutralization in obtaining compositions with the formation of viscous gels. Mainly drillholes, available from B. F. Goodrich Company as polycarbophil under the trade name “a Noveon”. The present invention mucoadhesive polymers are used in combination with acids to form a liquid with low viscosity, which after application to the tissue and mucous fluid forms a gel in situ.

In the composition of the present invention may also be water. Water used in the present invention should preferably be deionized and contain no organic contamination. Water is from about 50 to 99.99%, alternatively from about 80 to 99.95% and especially from about 95 to 99.9% by weight of the substance. This amount of water include the free water which is added plus the amount which is introduced with other materials.

When the composition of the present invention is a solid form, media can be used in powder form without the use of specific media. However, the media is often added to facilitate processing of compounds, to provide acceptable volatility and a particle size of more than 10 microns for nasal inhalation use. Other fine-grained or powdered pharmaceutically acceptable shall be volatility, stability, manipulation, hydroscopicity; suitable taste or smell. According to the present invention, the solid carrier is from about 0 to 99.99%, preferably from about 1 to 99.9%, alternatively from about 80 to 99% of the composition.

Chelating agents

The composition may include chelating agents to enhance antiviral activity by capturing metal ions viruses. Although this is not confirmed by theory, it can be assumed that the cations of the metals play a significant role in the formation of oxidizing species. The oxidative reaction and the formation of free radicals may contribute to cellular damage in inflammatory diseases. Chelating agents that can be used in the present invention are stable and effective in non-aqueous and aqueous medium and in the range of pH from 3 to 5. Specific chelating agents selected from the group consisting of phytic acid, disubstituted sodium and calcium salts of ethylenediaminetetraacetic acid (EDTU), chetyrehkamernoe sodium salt EDTU, sodium hexametaphosphate (GMFN=SHMP), di(hydroxyethyl)glycine, 8-hydroxyquinoline solution and mixtures thereof. According to the present invention, the data chelating and from 0.01 to 2% by weight of the composition.

Metal salts

Nasal compositions of the present invention may include a safe and effective amount of metal ions. It is known that metal ions such as iron, silver, copper and zinc, have antiviral properties. Zinc and its possible effect on the cold disclosed in The Handbook of Curing the Common Cold, George A. Eby, published 1994, George Eby Research, Texas, USA. Assume that the mechanisms of its action are multifactorial. It is shown that zinc ions are both antiviral and antibacterial. Believe that they inhibit the breakdown of rhinoviral polypeptides, preventing replication and the formation of infectious virions. Zinc ions reduce the ability of rhinoviruses to penetrate through the cell membrane, partly by lowering the expression of intercellular adhesion molecules ICAM. Also it is shown that zinc ions stimulate T-lymphocytes, including natural products antivirals - gamma-interferon. They stabilize cell membranes, protecting cells from cytotoxic agents, and prevent leakage of the cell. Metal ions can be in the form of salts or complexes with anions.

Suitable metal salts include as non-limiting ol the metal salts include metal salts, selected from the group consisting of cu, Fe, Zn and combinations thereof.

Metal salts include as non-limiting examples of physiologically acceptable salts of metals selected from the group consisting of salicylates, fumarates, benzoates, glutarate, lactates, citrates, malonates, acetates, glycolates, thiosalicylate, adipinate, succinate, gluconate, aspartate, glycine chelates of tartratami, malatov, malatov, ascorbates, chlorides, sulfates, nitrates, phosphates, fluorides, iodides, pidolate (Pidolate), and combinations thereof. In the alternative case, the metal salts are selected from the group consisting of acetates, ascorbates, chlorides, benzoate, citrate, gluconate, glucarate, lactates, malatov, malonates, salicylates, succinates and combinations thereof. In another alternative salts of metals selected from the group consisting of zinc acetate, zinc chloride, zinc ascorbate, zinc gluconate, pidolate (Pidolate), zinc and their combinations. Specifically included salt of a metal selected from the group consisting of salts of acetic acid, ascorbic acid, citric acid, gluconic acid, pyroglutamic acid, glutaric acid, salicylic acid or metal complexes of zinc, copper, tin, silver, iron and mixtures thereof.

In the compositions of the present invention, the metal salt is from about 0.001 to 20 wt.%. by weight of the composition, alternatively from about 0.01 to 10% and especially from about 0.05 to 2%. Alternative pyroglutamyl acid and metal salt can complexometry prior to the preparation of compositions of the present invention, thus forming a complex pyroglutamyl acid-metal. In this case, the complex is preferably present in an amount of about 0.001 to 20% by weight of the composition, alternatively from about 0.01 to 10% and especially from about 0.1 to 5%.

Examples

This is followed by non-limiting examples of compositions according to the present invention. All ingredients are listed by weight with respect to 100 grams of composition.

Example I.

Component % (wt./wt.)

PCA (pyroglutamyl acid) 1,00

Ascorbic acid 1,00

Phytic acid 1,00

Mucoadhesive11,00

Eucalyptol 0,01

Phenethyl alcohol 0,50

Water QS

1. Carbopol 980, available from B. F. Goodrich Company

Fill the bubbles with a pipette solution and close the lid. Inject 100 microliter solution in each nostril or nasal passage. Repeat three times a day.

Example II.

Component % (wt./wt.)

RSD (pyroglutamyl acid) 1,00

Ascorbic acid 1,00

Zinc acetate 0,33

Mucoadhesive polymer11,00

Eucalyptol 0,01

Water QS

1. Carbopol 980, available from B. F. Goodrich Company

Dispersivity Carbopol in chilled water. Add and dissolve the acid ingredients and zinc acetate with stirring. Pre-mix eucalyptol with phenethyl alcohol, and then add and dissolve with stirring. Bring the pH to 3.5 by adding sodium hydroxide.

Fill the bubbles with a pipette solution and close the lid. Inject 100 microliter solution in each nostril or nasal passage. Repeat three times a day.

Example III.

Component % (wt. /wt.)

PCA (pyroglutamyl acid) 1,00

Citric acid 0,50

Water QS

1. Carbopol 980, available from B. F. Goodrich Company

Instructions for production. Dispersivity Carbopol in chilled water. Add and dissolve the acid ingredients while stirring. Pre-mix eucalyptol with phenethyl alcohol, and then add and dissolve with stirring. Bring the pH to 3.5 by adding sodium hydroxide.

Fill the bubbles with a pipette solution and close the lid. Inject 100 microliter solution in each nostril or nasal passage. Repeat three times a day.

Example IV.

Component % (wt. /wt.)

PCA (pyroglutamyl acid) 1,00

Citric acid 0,50

Zinc acetate 0,33

Mucoadhesive polymer11,00

Eucalyptol 0,01

Phenethyl alcohol 0,50

Water QS

1. Carbopol 980, available from B. F. Goodrich Company

Instructions for production. Dispersivity Carbopol in chilled water. Add and dissolve the acid ingredients and zinc acetate with stirring. Pre-mix eucalyptol with phenethyl alcohol, and then add and dissolve with stirring. Bring the solution pH to 3.5 by adding sodium hydroxide.

Napo or nasal passage. Repeat three times a day.

Example V.

Component % (wt./wt.)

PCA (pyroglutamyl acid) 1,00

Sodium citrate 0,75

Eucalyptol 0,010

Ethanol 1,00

Powder lactose QS

Instructions for production. Mix PCA and sodium citrate together in a V-mixer for the formation of a homogeneous mixture. Grind the mixture in the mill variable power. Mix the crushed material with lactose by adding exponentially. Dissolve eucalyptol in ethanol and spray on top of the powder. Boil it put within ethanol by drying on a baking sheet. Mix SAR.

Fill in powder pumps, metering dry powder for nasal inhalation. Apply 10 milligrams of powder into each nostril or nasal passage.

Example VI.

Component % (wt./wt.)

PCA (pyroglutamyl acid) 1,00

Sodium citrate 0,75

Trioleate sorbitan 0,40

Propellants 97,85

Instructions for production. Mix PCA and sodium citrate together in a V-mixer for the formation of a homogeneous mixture. Grind the mixture in the mill variable power. Dissolve trioleate sorbitan in a mixture of propellants. Dispersivity mixture of PCA/aleatory under pressure using standard techniques of filling. Assign 100 microlitres of measuring the dosing inhaler in each nostril or nasal passage.

1. Laboratary nasal composition for the prevention and treatment of colds and influenza viral origin, including pyroglutamic acid in a concentration of from about 0.01 to 20% by weight of the composition, and an organic acid having a value of dissociation constant (pKa) of from 3.0 to 5.0, in the amount of from 0.01 to 10% by weight of the composition, and the combination of these pyroglutamyl and organic acids on the surface tissue of the nasal cavity pH value of from 3.5 to 5.5.

2. The composition according to p. 1, where the organic acid is selected from the group consisting of ascorbic acid, mono-, di-, and tricarboxylic acids, in particular salicylic, fumaric, benzoic, glutaric, lactic, citric, malonic, acetic, glycolic, malic, adipic, succinic, aspartic, phthalic, tartaric, glutamic, gluconic acid and mixtures thereof.

3. Composition under item 1 or 2, comprising a chelating agent in a concentration of from about 0.01 to 10% by weight of the composition, selected from the group consisting of phytic acid, disubstituted sodium and calcium salts ethylendiaminetetraacetic, 8-hydroxyquinoline solution and mixtures thereof.

4. Composition according to any one of paragraphs.1-3, including metal salts in a concentration of from 0.01 to 10% by weight of the composition, selected from the group consisting of acetates, ascorbates, chlorides, benzoate, citrate, gluconate, glucarate, lactates, malatov, malonates, salicylates, succinates and combinations thereof.

5. Composition according to any one of paragraphs.1-4, including mucoadhesive means selected from the group consisting of carboxypolymethylene, polymers of carboxyvinyl, of homopolymers of acrylic acid crosslinked allyl simple ether of pentaerythritol, of homopolymers of acrylic acid crosslinked allyl simple sucrose esters, homopolymers of acrylic acid crosslinked diphenylglycine and mixtures thereof, and the composition has a viscosity of less than 1000 SP and pH 3.5.

6. The method of prevention and treatment of colds and influenza viral origin, including the introduction by injection into the nasal passages of a subject composition under item 1.

 

Same patents:

The invention relates to the field of medicine and for the preparation of Bresolin drops nasal 0.06% and 0.1% for the treatment of diseases of the nose and throat

The invention relates to medicine, to the creation of new tools for the treatment of rhinitis

The invention relates to new guanidinium heterocyclic compounds of the formula (I), where R1denotes H, alkyl or is absent when R1missing link (a) is a double bond, D represents CR2, R2selected from H, alkyl, halogen, or, when is a CR3D can be N, denotes NR9, CR3=CR8, CR3, S, where R9denotes H, alkyl, alkenyl or quinil and where R3and R8selected from H, alkyl, alkenyl, quinil or cyano, R4, R5, R6each independently selected from H, alkyl, alkenyl, quinil, cyano, halogen or NH-C(= NR10)OTHER11(guanidine), R10and R11selected from H, methyl and ethyl, and where only one of R1, R5and R6is guanidines, R7selected from H, alkyl, alkenyl, quinil and halogen

The invention relates to the field of organic chemistry and medicine and relates to new quinoline derivatives of General formula I, where R represents unsubstituted C1-C3-alkyl or C2-C3alkenyl; R1is cyano, which are agonists alpha-2-adrenergic receptors and can be used when obtaining drugs suitable for the treatment of nasal congestion, glaucoma, diarrhea, asthma

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used as a means to reduce the risk of symptoms of menopausal syndrome

The invention relates to medicine, in particular to the pharmaceutical industry for the production of drugs therapeutic and prophylactic purposes, and can be used as an aid in facilitating the regulation of the respiratory system
The invention relates to medicine, namely to ophthalmology, and for the treatment of diabetic retinopathy
The invention relates to medicine, namely to ophthalmology, and for the treatment of progressive and complicated myopia
The invention relates to chemical-pharmaceutical industry, namely the creation of a multivitamin preparation with mineral additives
The invention relates to medicine and for the treatment of angina
The invention relates to medicine, namely oncodermatology, medical cosmetology, pharmacology
The invention relates to medicine and can be used for treatment of influenza
The invention relates to the treatment of non-insulin-dependent diabetes of adults (diabetes type II), in particular to the treatment of type II diabetes by the introduction of chromium picolinate and Biotin

The invention relates to the field of medicine

The invention relates to the field of pharmacology, and relates to pharmaceutical preparations for the treatment of gastritis, reflux esophagitis, duodenitis, dyspepsia and ulcers
The invention relates to medicine, namely oncodermatology, medical cosmetology, pharmacology

The invention relates to medicine, in particular to create a composition based on natural products with antovic and Antiherpes activity
Up!